Novadip Biosciences SA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novadip Biosciences SA
Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.
$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.
Start-ups raised $2.57 billion in Q3. Biopharma companies penned 23 alliances; 11 acquisitions were signed, none in the diagnostics industry.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced August through September 2015.
- Implantable Devices
- Gene Therapy, Cell Therapy